Oxaprozina [Inn-Spanish] en es it fr

Oxaprozina [Inn-Spanish] Brand names, Oxaprozina [Inn-Spanish] Analogs

Oxaprozina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Oxaprozina [Inn-Spanish] Chemical_Formula


Oxaprozina [Inn-Spanish] RX_link


Oxaprozina [Inn-Spanish] fda sheet

Oxaprozina_[Inn-Spanish] FDA

Oxaprozina [Inn-Spanish] msds (material safety sheet)

Oxaprozina_[Inn-Spanish] MSDS

Oxaprozina [Inn-Spanish] Synthesis Reference

No information avaliable

Oxaprozina [Inn-Spanish] Molecular Weight

293.317 g/mol

Oxaprozina [Inn-Spanish] Melting Point

158 - 159 oC

Oxaprozina [Inn-Spanish] H2O Solubility


Oxaprozina [Inn-Spanish] State


Oxaprozina [Inn-Spanish] LogP


Oxaprozina [Inn-Spanish] Dosage Forms


Oxaprozina [Inn-Spanish] Indication

Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.

Oxaprozina [Inn-Spanish] Pharmacology

Oxaprozin is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.

Oxaprozina [Inn-Spanish] Absorption

Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.

Oxaprozina [Inn-Spanish] side effects and Toxicity

Oral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg

Oxaprozina [Inn-Spanish] Patient Information

Daypro, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious gastrointestinal tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up.

Patients should report to their physicians the signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

In late pregnancy, as with other NSAIDs, Daypro should be avoided because it will cause premature closure of the ductus arteriosus.

Oxaprozina [Inn-Spanish] Organisms Affected

Humans and other mammals